Daiwa Comments On Johnson & Johnson Product Plan

According to Daiwa Capital Markets, Johnson & Johnson JNJ updated investors on its Pharmaceutical new product plan. Daiwa said that it rates JNJ 2. “We expect drug sales to be up 10.3% this year and 8.2% in 2012, driven by recently introduced drugs and by products currently in the advanced R&D. In MD&D we think JNJ can expand through new product introductions and growth in emerging markets. The consumer business is weak due to recall issues affecting OTC medicines but we expect Johnson & Johnson to gradually remediate this situation.” Johnson & Johnson closed yesterday at $66.77.